González-Guerrero Diana Elizabeth, Lazo-de-la-Vega-Monroy Maria-Luisa, Gómez-Ojeda Armando, Luévano-Contreras Claudia, Rojas-Rubio Armando, Garay-Sevilla Ma Eugenia
Department of Medical Science, Division of Health Science, University of Guanajuato, Campus León, León 36000, Mexico.
Biomedical Research Laboratory, Medicine Faculty, Catholic University of Maule, Talca 3605, Chile.
Metabolites. 2023 Apr 5;13(4):521. doi: 10.3390/metabo13040521.
RAGE is a multi-ligand transmembrane glycoprotein that promotes biological signals associated with inflammatory responses and degenerative diseases. sRAGE is a soluble variant, proposed as an inhibitor of RAGE activity. -374 T/A and -429 T/C polymorphisms of the advanced glycation end products receptor gene are associated with the development of some diseases, such as type of cancer, cardiovascular disease, and micro and macrovascular disease in diabetes among others but their role in metabolic syndrome (MS) is still unknown. We studied 80 healthy men without MS, and 80 men with MS according to the harmonized criteria. -374 T/A and -429 T/C polymorphisms were genotyped by RT-PCR, and sRAGE was measured by ELISA. Allelic and genotypic frequencies did not differ between Non-MS and MS groups (-374 T/A = 0.48, = 0.57 and -429 T/C = 0.36, = 0.59). Significant differences were found in fasting glucose levels and diastolic blood pressure among the genotypes of the -374 T/A polymorphism in the Non-MS group ( < 0.01 and = 0.008). Glucose levels were different between -429 T/C genotypes in the MS group ( = 0.02). sRAGE levels were similar in both groups, but in the Non-MS group showed a significant difference between individuals with only 1 or 2 components of the metabolic syndrome ( = 0.047). However, no associations of any SNP with MS were found (recessive model = 0.48, dominant model = 0.82 for -374 T/A; recessive model = 0.48, dominant model = 0.42 for -429 T/C). -374 T/A and -429 T/C polymorphisms are not associated with MS in Mexican population and have no influence on serum sRAGE levels.
晚期糖基化终产物受体（RAGE）是一种多配体跨膜糖蛋白，可促进与炎症反应和退行性疾病相关的生物信号。可溶性RAGE（sRAGE）是一种可溶性变体，被认为是RAGE活性的抑制剂。晚期糖基化终产物受体基因的-374 T/A和-429 T/C多态性与某些疾病的发生有关，如某些类型的癌症、心血管疾病以及糖尿病中的微血管和大血管疾病等，但它们在代谢综合征（MS）中的作用仍不清楚。我们根据统一标准研究了80名无MS的健康男性和80名患有MS的男性。通过逆转录聚合酶链反应（RT-PCR）对-374 T/A和-429 T/C多态性进行基因分型，并通过酶联免疫吸附测定（ELISA）测量sRAGE。非MS组和MS组之间的等位基因和基因型频率没有差异（-374 T/A：非MS组=0.48，MS组=0.57；-429 T/C：非MS组=0.36，MS组=0.59）。在非MS组中，-374 T/A多态性的基因型之间空腹血糖水平和舒张压存在显著差异（P<0.01和P = 0.008）。MS组中-429 T/C基因型之间的血糖水平不同（P = 0.02）。两组中的sRAGE水平相似，但在非MS组中，代谢综合征只有1种或2种组分的个体之间存在显著差异（P = 0.047）。然而，未发现任何单核苷酸多态性（SNP）与MS有关联（-374 T/A的隐性模型P = 0.48，显性模型P = 0.82；-429 T/C的隐性模型P = 0.48，显性模型P = 0.42）。-374 T/A和-429 T/C多态性与墨西哥人群的MS无关，且对血清sRAGE水平没有影响。
